Announcements
- Pharming Group reports fourth quarter and full year 2023 financial results
- Pharming Group to report fourth quarter and full year 2023 financial results on March 14
- Pharming Group to participate in February investor conferences
- Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
- Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
- Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
- Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval
- Pharming Group to participate in November investor conferences
- Pharming Group reports third quarter 2023 financial results
- Pharming Group to report third quarter 2023 financial results on October 26
More ▼
Key statistics
As of last trade Pharming Group NV (PHGN:DUS) traded at 1.01, 5.96% above its 52-week low of 0.9485, set on Apr 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.01 |
---|---|
High | 1.01 |
Low | 1.01 |
Bid | 1.01 |
Offer | 1.02 |
Previous close | 1.02 |
Average volume | 1.31k |
---|---|
Shares outstanding | 671.07m |
Free float | 657.05m |
P/E (TTM) | -- |
Market cap | 677.36m EUR |
EPS (TTM) | -0.0139 EUR |
Data delayed at least 15 minutes, as of Mar 28 2024 07:10 BST.
More ▼